TY - JOUR
T1 - Airway stenting for liberation from positive pressure ventilation in patients with central airway obstruction presenting with acute respiratory failure
AU - Salguero, Bertin D.
AU - Agrawal, Abhinav
AU - Kaul, Viren
AU - Lo Cascio, Christian M.
AU - Joy, Greta
AU - So, Matsuo
AU - Munagala, Rohit
AU - Harkin, Timothy
AU - Chaddha, Udit
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/4/1
Y1 - 2024/4/1
N2 - Background: Central airway obstruction (CAO) can lead to acute respiratory failure (RF) necessitating positive pressure ventilation (PPV). The efficacy of airway stenting to aid liberation from PPV in patients with severe acute RF has been scarcely published. We present a systematic review and our recent experience. Methods: A systematic review of PubMed was performed, and a retrospective review of cases performed at our two institutions from 2018 to 2022 in adult patients who needed stent insertion for extrinsic or mixed CAO complicated by RF necessitating PPV. Results: Fifteen studies were identified with a total of 156 patients. The weighted mean of successful liberation from PPV post-stenting was 84.5% and the median survival was 127.9 days. Our retrospective series included a total of 24 patients. The most common etiology was malignant CAO (83%). The types of PPV used included high-flow nasal cannula (HFNC) (21%), non-invasive ventilation (NIV) (17%) and Invasive Mechanical Ventilation (62%). The overall rate of successful liberation from PPV was 79%, with 55% of HFNC and NIV cases being liberated immediately post-procedure. The median survival of the patients with MCAO that were successfully liberated from PPV was 74 days (n = 16, range 3–893 days), and for those with that failed to be liberated from PPV, it was 22 days (n = 4, range 9–26 days). Conclusion: In patients presenting with acute RF from extrinsic or mixed morphology CAO requiring PPV, airway stenting can successfully liberate most from the PPV. This may allow patients to receive pathology-directed treatment and better end-of-life care.
AB - Background: Central airway obstruction (CAO) can lead to acute respiratory failure (RF) necessitating positive pressure ventilation (PPV). The efficacy of airway stenting to aid liberation from PPV in patients with severe acute RF has been scarcely published. We present a systematic review and our recent experience. Methods: A systematic review of PubMed was performed, and a retrospective review of cases performed at our two institutions from 2018 to 2022 in adult patients who needed stent insertion for extrinsic or mixed CAO complicated by RF necessitating PPV. Results: Fifteen studies were identified with a total of 156 patients. The weighted mean of successful liberation from PPV post-stenting was 84.5% and the median survival was 127.9 days. Our retrospective series included a total of 24 patients. The most common etiology was malignant CAO (83%). The types of PPV used included high-flow nasal cannula (HFNC) (21%), non-invasive ventilation (NIV) (17%) and Invasive Mechanical Ventilation (62%). The overall rate of successful liberation from PPV was 79%, with 55% of HFNC and NIV cases being liberated immediately post-procedure. The median survival of the patients with MCAO that were successfully liberated from PPV was 74 days (n = 16, range 3–893 days), and for those with that failed to be liberated from PPV, it was 22 days (n = 4, range 9–26 days). Conclusion: In patients presenting with acute RF from extrinsic or mixed morphology CAO requiring PPV, airway stenting can successfully liberate most from the PPV. This may allow patients to receive pathology-directed treatment and better end-of-life care.
KW - Airway stent
KW - Central airway obstruction
KW - Interventional bronchoscopy
KW - Interventional pulmonology
KW - Lung cancer
KW - Positive pressure ventilation
KW - Respiratory failure
UR - http://www.scopus.com/inward/record.url?scp=85188069440&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2024.107599
DO - 10.1016/j.rmed.2024.107599
M3 - Article
C2 - 38492817
AN - SCOPUS:85188069440
SN - 0954-6111
VL - 225
JO - Respiratory Medicine
JF - Respiratory Medicine
M1 - 107599
ER -